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Genetic associations with lipoprotein subfraction measures differ 
by ethnicity in the multi‑ethnic study of atherosclerosis (MESA)
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atherosclerosis (MESA). Genome-wide data were obtained 
using the Affymetrix 6.0 and Illumina HumanOmni chips. 
Linear regression models between genetic variables and 
lipoprotein subfractions were adjusted for age, gender, 
body mass index, smoking, study center, and genetic ances-
try (based on principal components), and additionally 
adjusted for Mexican/Non-Mexican status in HAs. A false 
discovery rate correction was applied separately within the 
results for each ethnicity to correct for multiple testing. 
Power calculations revealed that we did not have the power 
for SNP-based measures of association, so we analyzed 
phenotype-specific genetic risk scores (GRSs), constructed 
as in the original genome-wide analysis. We successfully 
Abstract A recent genome-wide association study asso-
ciated 62 single nucleotide polymorphisms (SNPs) from 
43 genomic loci, with fasting lipoprotein subfractions in 
European–Americans (EAs) at genome-wide levels of sig-
nificance across three independent samples. Whether these 
associations are consistent across ethnicities with a non-
European ancestry is unknown. We analyzed 15 lipoprotein 
subfraction measures, on 1677 African–Americans (AAs), 
1450 Hispanic–Americans (HAs), and 775 Chinese–Amer-
icans (CHN) participating in the multi-ethnic study of 
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replicated all 15 GRS–lipoprotein associations in 2527 
EAs. Among the 15 significant GRS–lipoprotein associa-
tions in EAs, 11 were significant in AAs, 13 in HAs, and 
1 in CHNs. Further analyses revealed that ethnicity differ-
ences could not be explained by differences in linkage dis-
equilibrium, lipid lowering drugs, diabetes, or gender. Our 
study emphasizes the importance of ethnicity (here index-
ing genetic ancestry) in genetic risk for CVD and high-
lights the need to identify ethnicity-specific genetic variants 
associated with CVD risk.
Introduction
Lipoproteins comprise a heterogeneous spectrum of particles, 
where each of the major lipoprotein fractions (i.e., very low-
density, intermediate-density, low-density, and high-density 
lipoproteins; VLDL, IDL, LDL, and HDL, respectively) can 
be further subdivided into small, medium, and large subfrac-
tions that differ in size, density, and lipid content (Berneis 
and Krauss 2002). Greater concentrations of small LDL and 
large VLDL particles, and lower concentrations of large HDL 
particles relative to the other subfractions, have been previ-
ously shown to be associated with an increase in the risk of 
cardiovascular disease (CVD) and insulin resistance (IR) 
states, including diabetes (Gray et al. 1997; Garvey et al. 
2003; Festa et al. 2005; Goff et al. 2005; Mora et al. 2009). 
Despite this evidence, the clinical utility of these and other 
lipoprotein particle measurements over more commonly used 
lipid and demographic measures is still uncertain (Krauss 
2010; Steffen et al. 2015). However, since lipoprotein sub-
fraction distributions are modifiable through therapeutic 
agents, as well as lifestyle (diet and exercise), they, nonethe-
less, represent a potential target for interventions aimed at 
reducing risk for CVD and IR (Beard et al. 1996; Lemieux 
et al. 2002; Melenovsky et al. 2002; Mauger et al. 2003; 
Wood et al. 2006). The associations between lipoprotein size 
and disease risk, coupled with the possibility that lipoprotein 
size may become a target for clinical interventions, have led 
to increased efforts to understand the etiology of lipoprotein 
subfraction heterogeneity.
In the most recent large-scale genome-wide association 
study (GWAS) meta-analysis, 62 SNPs from 43 genomic loci 
associated at genome-wide levels of significance with 22 lipo-
protein measures, including subfraction concentrations, frac-
tion diameters, and fraction particle numbers in a Caucasian 
population. Thirty-seven of the loci were replicated in two 
independent samples (Chasman et al. 2009). However, gen-
eralization of results from this GWAS is complicated for sev-
eral reasons. First, the discovery population was exclusively 
women, although the replication samples included both males 
and females. Second, there are known differences in genetic 
variants associated with lipoprotein subfraction sizes between 
ethnic groups, for example, a separate study suggested that 
variation in the hepatic lipase (LIPC) gene was associated 
with mean HDL diameter in European–Americans (EA), but 
not in Americans reported as being from Chinese, African or 
Hispanic ethnic groups (Frazier-Wood et al. 2013). Similarly, 
variants in the APOB gene region were significantly associ-
ated with mean VLDL diameter in EAs and Hispanic–Ameri-
cans (HA), this association was not present in Chinese nor 
African–Americans (CHN, AA, respectively) (Frazier-Wood 
et al. 2013). Such ethnic heterogeneity in gene–lipoprotein 
associations may reflect four possibilities: (1) the identity of 
single nucleotide polymorphisms (SNP) associated with dis-
ease risk or biomarkers differs across ethnic groups because 
of population differences in LD patterns (Aouizerat et al. 
2003; Goodarzi et al. 2003; Wung and Aouizerat 2003); (2) 
the directions of effects at such loci could be different across 
populations; (3) they may display magnitude inconsistencies; 
or (4) different environmental mediators may be present in 
the various groups. Together these suggest that extra care is 
needed when applying genetic risk models to non-Caucasians 
(Carlson et al. 2013).
Our aim is to investigate whether associations of pre-
viously validated genetic variants and lipoprotein sub-
fractions can be generalized to other ethnic populations, 
using data from the Multi-Ethnic Study of Atherosclerosis 
(MESA). Specifically, after replicating the associations of 
variants identified as associating with lipoprotein meas-
ures at genome-wide significance in Caucasians, and vali-
dated in two independent Caucasian samples (Chasman 
et al. 2009) in the EA population of MESA, we sought to 
examine these associations in the African-, Hispanic-, and 
Chinese populations of MESA, using both single SNP and 
summed genetic risk scores (GRS).
Materials and methods
Study population
The MESA study population consisted of 6814 men and 
women, ages 45–84 years, who self-identified as non-
Hispanic White (European Americans, EA), AA, HA, or 
CHN, and were recruited from six regions in the United 
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States from 2000 to 2002. The communities included For-
syth County, North Carolina; Northern Manhattan and the 
Bronx, New York; Baltimore City and Baltimore County, 
Maryland; St Paul, Minnesota; Chicago, Illinois; and 
Los Angeles County, California. MESA was designed to 
study the prevalence, risk factors, and progression of sub-
clinical CVD in a multi-ethnic cohort. A detailed descrip-
tion of the study design and methods has been published 
previously (Bild et al. 2002). All participants were free of 
clinically apparent cardiovascular disease. Clinical char-
acteristics, including anthropometric and blood-pressure 
measurements, were taken at the study clinics, where a 
fasting blood sample was also drawn. Questionnaires 
were administered at clinics to collect self-reported 
demographic data, including age, gender, race, country of 
origin, and information on lifestyle attributes and medical 
history. All participants gave informed consent, and the 
protocol was approved by the institutional review board 
of each of the study centers.
Biochemical measurements
Twelve hour fasting blood was drawn and serum, and 
EDTA-anticoagulant tubes were collected and stored at 
−70° using a standardized protocol (Bild et al. 2002). 
Lipoprotein subfractions, including the measurements 
of VLDL, LDL, and HDL diameter and subclass con-
centrations, were determined by nuclear magnetic res-
onance (NMR) spectroscopy by LipoScience (North 
Carolina, now LabCorp). This technique simultane-
ously quantifies the average particle size of lipoprotein 
fractions and concentration (“number”) of lipoprotein 
subfraction particles expressed each as an average par-
ticle diameter (in nanometers; nm) or as lipoprotein 
particle concentration (in mol/l), respectively (Otvos 
2001; Kuller et al. 2002; Mora et al. 2007; Mackey 
et al. 2012). NMR detects the signal emitted by lipo-
protein methyl-group protons when in the field of a 
magnet charged at 400 MHz. Particle concentrations 
of lipoproteins of different sizes were estimated from 
the deconvoluted NMR signals. Weighted-average lipo-
protein particle sizes are derived from the sum of the 
diameter of each subclass multiplied by its relative mass 
percentage based on the amplitude of its methyl NMR 
signal. NMR groups IDL as a subclass of LDL (Jeyara-
jah et al. 2006). In the original GWAS, Chasman and 
colleagues examined 15 lipoprotein subfraction meas-
ures determined by NMR together with LDL-C, HDL-C 
determined by NMR and enzymatic assay, triglycerides, 
ApoA1 and ApoB. Of these 15 lipoprotein subfractions, 
all 15 lipoprotein measures were assayed in MESA and 
included in the current analyses.
DNA collection protocol and genotyping
Although our analyses focus on candidate loci, we utilized 
data from the MESA GWAS protocol. Genomic DNA was 
isolated from whole blood for genetic analysis on all par-
ticipants. The quality of DNA was assessed by single SNP 
ABI TaqMan. Genome-wide data were obtained using the 
Affymetrix 6.0 chip and additional deeper sequencing using 
the Illumina HumanOmni chip. Exclusion criteria include 
heterozygosity >53% and individual-level genotyping call 
rate <95%. SNPs with call rate <95%, and monomorphic 
SNPs were removed. We further filtered on race/ethnic-
specific Hardy–Weinberg equilibrium p value >1 × 10−5. 
IMPUTE version 2.2.2 was used to perform imputation for 
the MESA SHARe participants (chromosomes 1–22) using 
1000 genomes as the reference panel. Imputed SNPs were 
filtered on observed/expected variance >0.5 derived from 
the MACH software (Li et al. 2010). Relationship infer-
ence was performed using the KING software (Manichai-
kul et al. 2010) to identify first- and second-degree rela-
tives, and an unrelated set of individuals was identified for 
genome-wide association data collection. All pairs of indi-
viduals with KING-inferred kinship coefficient >0.2 were 
identified as first-degree relatives. Based on this criterion, 
all first-degree relatives were grouped into families, and an 
unrelated subset of individuals was constructed by choos-
ing at most one individual from each family.
Statistics
All analyses were performed using SAS 9.4 (SAS Institute, 
Cary, NC, USA).
Sample characteristics
To examine whether the ethnic groups differed by age, we 
performed t tests, with the exception of ethnicity differ-
ences by gender that were examined using a 2-degree of 
freedom (df) Chi-square (χ2) test. These tests revealed sig-
nificant age differences by ethnicity (Table 1). Since both 
age and gender were associated with lipoprotein measures 
in our sample (data not shown), analyses examining eth-
nicity differences in lipoprotein measures (also presented 
in Table 1) were examined using regression models with 
mean lipoprotein measure as the outcome and age and gen-
der as covariates.
Log-transformations or square-root transformations 
were used when lipoprotein measures exhibited (residual) 
deviations from normality. Concentrations of large VLDL 
and large HDL particles were log-transformed, concen-
trations of medium and small VLDL, and medium HDL, 
as well as total VLDL, IDL, and HDL particles were 
square root transformed. We inspected graphical methods 
718 Hum Genet (2017) 136:715–726
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including histograms, and interpreted statistics including 
skewness and kurtosis to formally test for normality after 
transformation.
Since ethnicity was self-reported, within the full 
MESA cohort, we stratified by ethnic group and 
eliminated those individuals with top principal com-
ponents (PCs) of ancestry >3.5 SD from the mean 
within any ethnic group. Details about the race/eth-
nic-specific PCs of ancestry used for adjustment have 
been reported previously (Manichaikul et al. 2012). 
Briefly, we constructed subsets of genotyped SNPs 
after LD-pruning for each ethnic group. Regions of 
long-range LD were removed, and local LD structures 
were thinned using a pairwise R2 of no more than 
0.2 in a 100 SNP window, moving at 25 SNP blocks. 
SMARTPCA (Patterson et al. 2006; Price et al. 2006) 
within EIGENSTRAT was used to compute PCs. 
Based on previous examination in MESA, we used 3 
PCs for EAs, 1 PC for AAs, 3 PCs for HAs, and 1 
PC for CHNs and finally eliminated 22 individuals 
from EAs, 3 from AAs and 1 from HAs due to being 
more than 3.5 SD from the mean PC value within that 
ethnic group. All models controlled for age, gender, 
BMI, current smoking status, study center, and princi-
pal components of ancestry (PCs, PC1–PC4) as fixed 
effects. In HAs, models were additionally adjusted for 
Mexican/Non-Mexican status.
SNP–lipoprotein associations
To examine genetic associations, we first fitted linear 
model with lipoprotein subfraction measures as the out-
come and individual SNPs as the predictor. Initially, we 
explored the association between individual SNPs as 
Table 1  Means (±standard deviation), or percentages for demographic characteristics, and fasting lipid traits and lipoprotein diameters for the 
MESA study participants
a
 EA: European American
b
 AA: African American
c
 HA–Hispanic American
d
 CA: Chinese American
e
 Significant (p < 0.05) differences between: 1: EAs and AAs; 2: EAs and HAs; 3: EAs and CHNs; 4: AAs and HAs; 5: AAs and CHNs; and 6: 
HAs and CHNs participants in t tests (age), χ2 test (gender), and regression model (lipoprotein measures) of ethnicity difference
EAsa AAsb HAsc CHNsd Ethnicity differencese
N 2527 1677 1450 775 –
Gender (% male) 47.7 46.0 48.4 49.2
Age (years) 62.7 (10.2) 62.2 (10.1) 61.4 (10.3) 62.4 (10.4) 2, 4, 6
Lipid lowering drugs (% taking) 18.3 16.0 13.4 14.1 –
Hypertension (% yes) 38.6 59.2 41.9 37.7 –
Triglycerides (mg/dl) 133.05 (90.10) 104.90 (69.91) 158.19 (101.75) 143.00 (85.67) –
VLDL large (nmol/L) 5.34 (6.71) 3.17 (4.17) 7.03 (7.47) 4.64 (6.81) 1, 2, 3, 4, 5, 6
VLDL medium (nmol/L) 28.78 (21.41) 21.07 (17.11) 32.80 (21.39) 39.57 (26.90) 1, 2, 3, 4, 5, 6
VLDL small (nmol/L) 34.12 (19.72) 29.21 (18.60) 35.95 (20.41) 41.49 (20.66) 1, 2, 3, 4, 5, 6
VLDL total (nmol/L) 68.24 (36.41) 53.45 (32.48) 75.78 (37.08) 85.71 (38.25) 1, 2, 3, 4, 5, 6
IDL total (nmol/L) 131.02 (101.76) 116.12 (90.11) 138.60 (107.29) 112.61 (89.12) 1, 2, 3, 4, 6
LDL large (nmol/L) 607.23 (259.65) 603.29 (251.01) 549.06 (270.45) 537.02 (239.85) 2, 3, 4, 5
LDL small (nmol/L) 505.88 (373.85) 497.24 (372.01) 631.88 (400.40) 552.09 (374.26) 2, 3, 4, 5, 6
LDL total (nmol/L) 1244.12 (324.50) 1216.67 (359.23) 1319.51 (347.43) 1201.73 (311.64) 1, 2, 3, 4, 6
HDL large (µmol/L) 6.09 (3.60) 6.41 (3.61) 5.35 (3.03) 6.03 (3.09) 1, 2, 4, 5, 6
HDL medium (µmol/L) 14.99 (7.44) 11.86 (6.05) 13.39 (6.50) 10.92 (5.74) 1, 2, 3, 4, 5, 6
HDL small (µmol/L) 13.95 (5.96) 15.24 (5.42) 14.47 (5.46) 16.69 (5.57) 1, 2, 3, 4, 5, 6
HDL total (µmol/L) 35.03 (7.06) 33.50 (6.51) 33.20 (6.27) 33.63 (5.85) 1, 2, 3
VLDL diameter (nm) 49.11 (8.39) 47.29 (6.72) 50.91 (8.54) 46.34 (7.18) 1, 2, 3, 4, 5, 6
LDL diameter (nm) 20.81 (0.56) 20.79 (0.51) 20.64 (0.58) 20.61 (0.51) 2, 3, 4, 5
HDL diameter (nm) 9.25 (0.46) 9.30 (0.49) 9.16 (0.43) 9.29 (0.41) 1, 2, 3, 4, 6
LDL-cholesterol (mg/dl) 117.10 (30.28) 116.47 (33.17) 119.82 (32.87) 115.10 (28.80) –
HDL-cholesterol (mg/dl) 52.40 (15.76) 52.34 (15.16) 47.51 (13.04) 49.33 (12.41) –
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in the original GWAS (Chasman et al. 2009) with lipo-
protein measures in EAs. As in the original GWAS, the 
minor allele in EAs was coded as 1 and major allele 
was coded as 0 in an additive model. Subsequently, the 
associations were conducted in the other ethnic popula-
tions of the MESA. As the original associations reported 
by Chasman et al. (2009) may have reported an SNP–
lipoprotein association, where the SNP was not directly 
associated with the outcome, but rather in linkage dis-
equilibrium (LD) with the causal SNP, and because LD 
structures differ between ethnic groups (The Interna-
tional HapMap Consortium 2003), where SNP–lipopro-
tein associations were not significant at an FDR cor-
rected Q < 0.05, we examined associations using proxy 
SNPs identified using SNAP (Johnson et al. 2008) which 
were in LD at R2 > 0.8 in EAs, but not in the other eth-
nicities, and so may not be indexed by the identified 
SNP. An FDR correction was used within each ethnic 
group on p values for all associations including those 
with proxy SNPs.
GRS–phenotype associations
Unweighted GRSs were constructed and presented as 
our main results as they may be more robust against 
errors in estimating the effect sizes arising from lim-
ited sample sizes, and may be more suitable for reduc-
ing increased estimates of association due to population 
heterogeneity, population substructure, and “winner’s 
curse” (Dudbridge 2013). When constructing the GRSs, 
the constituent genotypes were rescored to have the 
same effect on the phenotype, based on the direction 
reported in the original GWAS (Chasman et al. 2009). 
The major allele was kept as the coded allele when the 
regression coefficient in the original GWAS (Chasman 
et al. 2009) was negative for a given SNP–lipoprotein 
association; the minor allele remained the coded allele 
when the original regression coefficient was positive. 
Whether the direction of our reported regression coeffi-
cient is consistent with the direction of the original coef-
ficient is shown in S1 Table. This resulted in genotypes 
being scored both ways (with the minor allele and the 
major allele as the coded allele) based on the particular 
phenotype. Subsequently, we created GRS by summing 
the alleles of either the SNP from associations reported 
in EAs, or from a proxy SNP, where the original SNP–
lipoprotein association was null (Q > 0.05), but the 
proxy SNP was significantly associated with lipoprotein 
subfraction measures at Q < 0.05. An FDR correction 
was used within each ethnic group, and corrected q val-
ues were reported (Benjamini and Hochberg 1995; Sto-
rey and Tibshirani 2003).
Power analysis for genetic associations
We conducted power analyses to estimate our power to 
detect associations in the MESA cohort for SNPs associ-
ated with lipoprotein measures in EAs from the original 
GWAS (Chasman et al. 2009). Power analyses were con-
ducted using Quanto v 1.2.4 (Gauderman and Morrison 
2001; Gauderman 2002) with Type I error 0.05 (thus our 
power calculation indicated ‘nominal significance’, i.e., 
not corrected for the number of independent tests). The 
observed effect sizes (β) from the SNP–lipoprotein asso-
ciations in the Caucasian population of the original GWAS 
(Chasman et al. 2009), as well as the observed minor allele 
frequency (MAF) for each of the ethnic populations of 
MESA were used to calculate our power to replicate SNP–
lipoprotein associations of the same or larger effect size 
across ethnicities. Our power estimates showed that we had 
limited (<80%) power for majority single SNP–phenotype 
associations (S1 Table); therefore, we present individual 
SNP–phenotype associations as supplementary data and 
focus on results using GRSs for each lipoprotein pheno-
type, since GRSs may have increased power over single 
SNP associations (Chasman et al. 2009; Frazier-Wood et al. 
2014). Power analyses for GRS–lipoprotein associations 
were conducted in G*Power version 3.1.9.2 (Faul et al. 
2007, 2009) specifying R2 for the GRS–lipoprotein associ-
ation in the fasting subsample in the original GWAS (Chas-
man et al. 2009) and Bonferroni corrected Type I error 
0.05/15 = 0.0033, in a linear regression model, including 
ten predictors for European-, African-, and Chinese-ethnic 
group individuals: GRS, age, gender, BMI, current smok-
ing status, study centers, and PC1–PC4. We specified 11 
predictors in HAs as we included country of origin (Mexi-
cans or non-Mexican Hispanics) in the model.
Results
Demographic characteristics in MESA
General characteristics of the MESA study participants are 
summarized in Table 1. There were no gender differences 
by ethnicity, but there were small (although statistically 
significant, P < 0.05) age differences (Table 1). For the 
15 lipoprotein subfractions examined, we saw significant 
ethnic differences between all populations in seven sub-
fractions: large VLDL, medium VLDL, small VLDL and 
VLDL total particles; medium and small HDL particles; 
and mean VLDL diameter (P < 0.05; Table 1). For the other 
subfractions, as whole we still observed a general pattern 
of differences between the ethnic groups, although in a few 
cases, these did not reach significance.
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Replication of previous genetic findings in EAs
Some SNPs associated with more than one lipopro-
tein measure in the original GWAS. We included the 62 
unique SNPs which associated with at least one of the 
15 phenotypes available in our data, leading to a total 
of 131 SNP–lipoprotein association models, to be run in 
the Caucasian population. One SNP (rs3129882) in the 
original GWAS is not available in our genotype data. 
We conducted a proxy SNP search using SNAP (John-
son et al. 2008), however, that query SNP is not in 1000 
Genomes Pilot1 and there were no matching proxy SNPs 
found. Therefore, it was excluded from analysis. Ini-
tially, we replicated 59 out of 131 (45%) of the SNP–
lipoprotein associations at an FDR-adjusted Q < 0.05 
(S1 Table; Chasman et al. 2009). Only the association of 
rs7706174 and large LDL particle differed in direction 
as the previous GWAS, and was significant (Q < 0.05). 
However, which variant was the coded allele in the pre-
vious GWAS was not reported for this locus. It is pos-
sible that the different direction of this association might, 
therefore, be due to differences in allele coding between 
the original study and ours. Power analyses suggested 
that some of the non-replication may have been due to 
statistical power, as our power was less 80% in ~60% of 
SNP–lipoprotein associations in MESA EAs (S2 Table). 
However, using GRSs, we had over 99% power to detect 
the GRS–lipoprotein associations detected in the original 
GWAS in MESA EAs (S3 Table; Chasman et al. 2009). 
All GRS–lipoprotein associations were significant at an 
FDR Q < 0.05 (Table 2), suggesting that overall, the same 
genetic effects were operating on lipoprotein subfractions 
in our EA population as in the previous GWAS (Chasman 
et al. 2009; Table 2).
Examination of associations in other ethnicities
SNP–lipoprotein associations 15 out of 131 original 
SNP–lipoprotein associations were significant after mul-
tiple testing correction (FDR Q < 0.05) in AAs, 37 out 
of 131 were significant in HAs, and 1 out of 131 were 
significant in CHNs (S1 Table). For those SNP–lipopro-
tein associations that were not significant after account-
ing for multiple testing, we conducted the associations 
using proxy SNPs (S4–7 Table). From these proxy SNPs, 
we saw only two additional proxy SNP–lipoprotein asso-
ciations in CHNs (rs676210—small VLDL particle and 
rs673548—small VLDL particle; original SNP rs6754295 
(both Q < 0.05; S6 Table). As no other significant SNP–
lipoprotein association was reported with proxy SNPs, 
we did not include proxy SNPs in the next step of GRS 
calculations.
GRS–lipoprotein associations We had over 95% 
power to detect GRS–lipoprotein associations in AAs, 
HAs, and CHNs based on the effect size reported in the 
GWAS meta-analysis (S3 Table). For AAs, 11 out of 
15 GRS–lipoprotein associations were significant at an 
FDR Q < 0.05 (Table 2). Specifically, the GRS associa-
tions with most VLDL subfraction measures, including 
concentrations of large, small, and total VLDL particles, 
as well as mean VLDL diameters, were not significant 
in AAs. Almost all of (13 out of 15) GRS–lipoprotein 
associations were significant at an FDR Q < 0.05 in HAs 
except for the association with total IDL particle concen-
tration and medium HDL particle concentration. Only 1 
out of 15 GRS–lipoprotein associations were significant 
at an FDR Q < 0.05 in CHNs, which is the GRS associa-
tion with concentration of total IDL particles (Table 2).
Secondary analyses
We considered the potential modifying effects of lipid 
lowering drugs, diabetes, and gender in the association of 
genetic variants with lipoprotein subfraction measures. In 
secondary analyses, we additionally excluded MESA par-
ticipants on lipid lowering medications and those with type 
2 diabetes (Malave et al. 2012) at baseline to minimize 
environmental influences on lipoprotein subfraction meas-
ures. Although we observed moderately attenuated associa-
tions with smaller coefficients, the overall pattern of results 
for GRS–lipoprotein associations was not substantially dif-
ferent from the primary analyses (S8 Table). In addition, 
as the original GWAS included only female participants 
(Chasman et al. 2009), we conducted gender-stratified anal-
yses for the GRS–lipoprotein associations (S9 Table). only 
a very small number of cases were the GRS–lipoprotein 
associations significant for one gender, but not the other 
(S9 Table). In which case, we tested for a statistical interac-
tion between gender and GRS in the associations. We did 
not observe any significant interactions with gender after 
multiple testing correction, justifying our inclusion of both 
genders in the main analyses, but as these analyses are lim-
ited in power, we do not draw main conclusions from the 
lack of an interaction (S9 Table).
Discussion
This study replicated SNP–lipoprotein and GRS–lipopro-
tein associations previously validated in EAs (Chasman 
et al. 2009), and further investigated whether those asso-
ciations could be generalized to Hispanic-, African-, and 
Chinese-ethnic groups living in the US. We provide evi-
dence that there is heterogeneity in the genetic basis of the 
lipoprotein subfractions across ethnic groups: among the 
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15 significant associations between GRSs and lipoprotein 
subfraction phenotypes in EAs, 11 showed significant asso-
ciations in AAs, 13 in HAs, and only 1 in CHNs.
In our initial analyses, we replicated 45% of the origi-
nal SNP–lipoprotein associations in EAs (at an FDR-
adjusted significance level), and even less in AAs, HAs, 
and CHNs. Numerous reasons could account for the fail-
ure to replicate remaining SNPs; for example, the limited 
statistical power we had in replicating and examining 
individual SNP–lipoprotein associations, or sample dif-
ferences between our cohort and those of the discovery 
GWAS (notably ours was of mixed gender). We did ten-
tatively explore the possibility that for significant asso-
ciations in EAs, the lack of replication in the other ethnic 
groups arose from the putatively causal SNP not being 
genotyped in the original discovery efforts, possibly cre-
ating differential associations due to variable LD patterns 
across the ethnic groups (Tam and Consortium 2003; Fra-
zier-Wood and Rich 2015). However, we did not observe 
many proxy SNP–lipoprotein associations that reached 
an FDR-adjusted significance level, with the exception 
of the associations of two proxy SNPs (rs676210 and 
rs673548) with concentration of small VLDL particles 
in CHNs. Although 131 association tests may be con-
sidered modest in the GWAS era, our sample size may 
also be considered modest for genetic analysis too. Given 
this, even with an FDR correction for multiple testing, 
we cannot rule out the possibility that these two associa-
tions are false positives Therefore, the lack of significant 
proxy SNP associations suggests that we cannot provide 
evidence that the heterogeneity in genetic effects for lipo-
protein subfraction measures is due to differences in LD 
structure across ethnicities.
Despite the fact that only some of the previous SNP–
lipoprotein associations were significantly replicated in our 
data, we did have more than 95% power to detect GRS–
lipoprotein associations. All GRS–lipoprotein associations 
we examined were significant in EAs, validating the pre-
vious findings by (Chasman et al. 2009). Most were sig-
nificant in HAs; however, the GRS association with most 
VLDL subfraction measures, including concentrations of 
large VLDL and small VLDL particles, VLDL total par-
ticles, and VLDL diameters, was not significant in AAs 
and CHNs. In addition, none of the examined GRS–lipo-
protein associations were significant in CHNs except for 
the GRS association with concentration of total IDL par-
ticles. The differing GRS–lipoprotein associations we 
observed, given that we considered the role of ethnicity-
specific LD structure in our GRS creations, suggests that 
overall, the genetic effects on lipoprotein subfractions were 
most similar between HAs and EAs. Some of the genetic 
effects on lipoprotein subfractions in AAs did mirror those 
of EAs, but to a lesser extent than did those of the HIS 
group. AA associations also had some similarities to those 
seen in the HIS group, although again, this was to a small 
extent. CHNs largely differed from the ones in EAs, with 
only one GRS–lipoprotein association, from those GRSs 
derived in EA populations being significant in the CHN 
group. Although we must emphasize the small size of the 
CHN population in this study, our findings are, nonethe-
less, consistent with the literature about genetic structures 
and differentiation across ethnicities, which found distinct 
and non-overlapping clustering of the Caucasian, African–
American and Chinese samples in the US (Mountain and 
Cavalli-Sforza 1997; Jorde and Wooding 2004; Shriver 
et al. 2004), while Hispanics, who represent a recently 
admixed group between Native Americans, Caucasians, 
and Africans, did not form a distinct subgroup (Hanis et al. 
1991; González Burchard et al. 2005), and, therefore, are 
expected to be more genetically similar to EAs than CHNs 
and AAs.
There is currently a dearth of studies that have inves-
tigated ethnic heterogeneity in genetic associations with 
lipoprotein subfraction measures. To the best of our knowl-
edge, only one such study has been conducted: they found 
that the variants in the APOB gene region were associated 
with mean VLDL diameter in EAs and HAs, but not in AAs 
and CHNs, while variation in the LIPC gene was sugges-
tively associated with mean HDL diameters only in EAs 
(Frazier-Wood et al. 2013). Thirty-seven of the lipoprotein-
associated loci included that the current analyses are also 
robustly associated with lipids in Caucasian populations 
(Teslovich et al. 2010; Global Lipids Genetics 2013); we 
find mixed evidence on whether these variants also associ-
ate with lipids in other ancestry populations (Keebler et al. 
2009; Lanktree et al. 2009; Teslovich et al. 2010; Chang 
et al. 2011; Dumitrescu et al. 2011; Musunuru et al. 2012; 
Bryant et al. 2013; Wu et al. 2013; Below et al. 2016). Some 
of these studies were able to replicate the same associations 
(or at minimally identify directionally consistent effects) 
identified in EAs in non-European ancestry populations 
(Keebler et al. 2009; Lanktree et al. 2009; Teslovich et al. 
2010; Bryant et al. 2013); for example, the associations 
between lipids and variants in APOB as well as PPP1R3B 
genes that were identified in EAs were well replicated in 
HISs and AAs (Teslovich et al. 2010; Bryant et al. 2013). 
However, several multi-ethnic analyses of lipid-associ-
ated loci had reported that the specific-associated variants 
often differed across ethnicities (Teslovich et al. 2010; 
Dumitrescu et al. 2011; Musunuru et al. 2012; Bryant et al. 
2013; Wu et al. 2013). Interestingly, several lipids genes 
identified from large European ancestry GWAS, including 
APOC1-APOE, MAFB, LIPG, etc, were observed to have 
differential association among East Asians (Teslovich et al. 
2010), which are consistent with our results suggesting that 
CHNs largely differed from the ones in EAs. A trans-ethnic 
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fine-mapping study of lipid loci identified different variants 
in the PCSK9 and APOA5 genes that influenced LDL-C 
levels in Europeans and AAs (Wu et al. 2013). This empha-
sizes the need for more research on the transferability of 
SNPs across ancestry groups, and we hope that the data 
here eventually contribute to a broader body of evidence on 
this issue than is currently available.
The strengths of this study include the large multi-eth-
nic population, and it is one of the first studies focusing 
on ethnicity difference of genetic associations with a full 
profile of lipoprotein subfraction measures. In addition, 
eliminating those individuals with top principal compo-
nents (PCs) of ancestry >3.5 SD from the mean within 
each ethnic group minimizes the misclassification of self-
report ancestry. However, there are some limitations that 
must be considered upon interpreting our results. First, 
we were underpowered to fully replicate all the previous 
individual SNP–phenotype associations: our EA group 
was smaller than in the original EA GWAS, the other 
ethnic groups were smaller still, and our total number of 
participants may have been slightly smaller than neces-
sary due to the use of the KING software to remove close 
relatives over an approach based on graph theory (Staples 
et al. 2013). This sample size issue is particularly perti-
nent to the CHN group. However, our GRS analysis was 
well-powered and showed significant GRS–phenotype 
associations in EAs. In addition, even though the imputa-
tion quality was well controlled in EAs with an observed/
expected variance greater than 0.5, 3 out of 61 SNPs in 
CHNs and 1 out of 61 SNPs in AAs had low imputation 
quality (Supplementary Table 10) and may contribute to 
failure of replication in these two ethnicity groups. How-
ever, given the GRS-based results to which these SNP 
contribute very little variance, it is not likely that very few 
SNPs of lowered imputation quality adversely affect our 
results.
In addition, as suggested by the gender-specific effect 
on genetic basis of lipid profiles and metabolic syn-
drome (McCarthy et al. 2003; Wung and Aouizerat 2003; 
Aulchenko et al. 2009), there could be increased heter-
ogeneity due to gender effects in our population when 
compared to the original GWAS (Chasman et al. 2009), 
since the original GWAS was conducted in a sample of 
exclusively women. We attempted to explore the GRS–
lipoprotein associations stratified by gender. However, 
due to the reduced sample size in stratified analysis, we 
could not draw any firm conclusions and encourage fur-
ther research into this. Finally, we were unable to explore 
reasons for the ethnic heterogeneity in SNP–lipoprotein 
associations observed and the roles of non-genetic differ-
ences between the populations, gene–gene interactions, 
and gene–environment interactions would form impor-
tant directions for future research (Ma et al. 2012). Our 
study emphasizes the need for future studies for associa-
tions with lipoprotein subfraction measures in non-Cau-
casian populations, which may identify novel SNPs. Such 
work may help to better understand ethnic differences in 
CVD risk, and may elucidate different pathways to risk 
between the groups.
In conclusion, associations between GRS and lipo-
protein subfraction measures largely differed by self-
reported ethnicity except between HAs and EAs. The 
observed differences may be due to unidentified genetic 
influences on lipoproteins in ethnic groups with differ-
ing genetic ancestries, or other factors, such as gene–
environment interactions. Our study highlights the need 
for future research which investigates ethnicity-specific 
SNPs associated with CVD risk, leading to the possibility 
of ethnicity- (and potentially ancestry-) stratified predic-
tion and precision treatment.
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